Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
Introduction Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly meani...
| 出版年: | BMJ Open |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
BMJ Publishing Group
2022-10-01
|
| オンライン･アクセス: | https://bmjopen.bmj.com/content/12/10/e066019.full |